Search News Archives
Special Offers and Promotions
Conferences | Events
Mutant Spike Proteins & Antigens for SARS-CoV-2 Variant Research
AMSBIO has introduced a collection of mutated SARS-CoV-2 spike proteins and recombinant antigens for the new virus variants - B.1.1.7 and B.1.351. These reagents can be used by researchers to evaluate the efficacy of the antibodies and identify targets for development of improved therapeutic drugs and vaccines.
Emerging in the latter part of 2020, multiple new SARS-CoV-2 variants are now circulating globally. Most notably in the UK, a new variant strain of SARS-CoV-2 (known as B.1.1.7) emerged with an unusually large number of mutations. This variant has since been detected in numerous countries around the world, including the United States and Canada. In South Africa, another variant of SARS-CoV-2 (known as B.1.351) emerged independently of the B.1.1.7 lineage. This variant shares some mutations with the B.1.1.7 lineage. Cases attributed to this variant have now been detected outside of South Africa.
While it is known and expected that viruses constantly change through mutation leading to the emergence of new variants, analysis has shown that these new SARS-CoV-2 variants are significantly more transmissible than previously circulating variants, and may pose a challenge to current generation COVID-19 vaccines.
The new collection of mutant spike proteins and antigens for SARS-CoV-2 variant research are supplied highly purified as verified by SDS-PAGE data. New products for B.1.1.7 research include mutated SARS-CoV-2 S protein, S1 protein, S1 protein NTD, S1 protein RBD and nucleocapsid protein. For research into the South African variant (B.1.351) - mutated SARS-CoV-2 S protein, S1 protein, S1 protein NTD and S1 protein RBD are available.
About AMS Biotechnology (AMSBIO)
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3Dculture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.